{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:33:18Z","timestamp":1792805598841,"version":"4.5.0"},"reference-count":163,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T00:00:00Z","timestamp":1675814400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency Research","doi-asserted-by":"publisher","award":["P3-0427"],"award-info":[{"award-number":["P3-0427"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"Slovenian Research Agency Research","doi-asserted-by":"publisher","award":["J3-9272"],"award-info":[{"award-number":["J3-9272"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Molecular diagnostic tests help clinicians understand the underlying biological mechanisms of their patients\u2019 breast cancer (BC) and facilitate clinical management. Several tissue-based mRNA tests are used routinely in clinical practice, particularly for assessing the BC recurrence risk, which can guide treatment decisions. However, blood-based mRNA assays have only recently started to emerge. This review explores the commercially available blood mRNA diagnostic assays for BC. These tests enable differentiation of BC from non-BC subjects (Syantra DX, BCtect), detection of small tumours &lt;10 mm (early BC detection) (Syantra DX), detection of different cancers (including BC) from a single blood sample (multi-cancer blood test Aristotle), detection of BC in premenopausal and postmenopausal women and those with high breast density (Syantra DX), and improvement of diagnostic outcomes of DNA testing (variant interpretation) (+RNAinsight). The review also evaluates ongoing transcriptomic research on exciting possibilities for future assays, including blood transcriptome analyses aimed at differentiating lymph node positive and negative BC, distinguishing BC and benign breast disease, detecting ductal carcinoma in situ, and improving early detection further (expression changes can be detected in blood up to eight years before diagnosing BC using conventional approaches, while future metastatic and non-metastatic BC can be distinguished two years before BC diagnosis).<\/jats:p>","DOI":"10.3390\/cancers15041087","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T06:00:05Z","timestamp":1675836005000},"page":"1087","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0099-0940","authenticated-orcid":false,"given":"Helena","family":"\u010cele\u0161nik","sequence":"first","affiliation":[{"name":"Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, 2000 Maribor, Slovenia"},{"name":"Center for Human Genetics & Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-9428","authenticated-orcid":false,"given":"Uro\u0161","family":"Poto\u010dnik","sequence":"additional","affiliation":[{"name":"Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova Ulica 17, 2000 Maribor, Slovenia"},{"name":"Center for Human Genetics & Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska Ulica 8, 2000 Maribor, Slovenia"},{"name":"Department for Science and Research, University Medical Centre Maribor, Ljubljanska Ulica 5, 2000 Maribor, Slovenia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.annonc.2021.12.007","article-title":"European cancer mortality predictions for the year 2022 with focus on ovarian cancer","volume":"33","author":"Dalmartello","year":"2022","journal-title":"Ann Oncol."},{"key":"ref_2","unstructured":"International Agency for Research on Cancer, WHO (2022, October 19). Cancer Today. Available online: https:\/\/gco.iarc.fr\/today\/home."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/cge.13900","article-title":"Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review","volume":"99","author":"Szymiczek","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/cancers14030591","article-title":"Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer","volume":"14","year":"2022","journal-title":"Cancers"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/OP.21.00384","article-title":"Clinical Review on the Management of Hormone Receptor-Positive Metastatic Breast Cancer","volume":"18","author":"McAndrew","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3390\/curroncol29040222","article-title":"Novel Therapies for the Treatment of HER2-Positive Advanced Breast Cancer: A Canadian Perspective","volume":"29","author":"Ferrario","year":"2022","journal-title":"Curr. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer\u2014expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_8","unstructured":"\u010cele\u0161nik, H.S., and Poto\u010dnik, U. (2022, November 27). Immunotherapy in Breast Cancer. In: Encyclopedia. Available online: https:\/\/encyclopedia.pub\/entry\/21561."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Skok, K., Gradi\u0161nik, L., \u010cele\u0161nik, H., Milojevi\u0107, M., Poto\u010dnik, U., Jezernik, G., Gorenjak, M., Sobo\u010dan, M., Taka\u010d, I., and Kavalar, R. (2021). MFUM-BrTNBC-1, a Newly Established Patient-Derived Triple-Negative Breast Cancer Cell Line: Molecular Characterisation, Genetic Stability, and Comprehensive Comparison with Commercial Breast Cancer Cell Lines. Cells, 11.","DOI":"10.3390\/cells11010117"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/tbj.13695","article-title":"Isolation and characterization of the first Slovenian human triple-negative breast cancer cell line","volume":"26","author":"Skok","year":"2020","journal-title":"Breast J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18632\/oncotarget.27877","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer","volume":"12","author":"Tolaney","year":"2021","journal-title":"Oncotarget."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4137\/CIN.S9983","article-title":"TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer","volume":"11","author":"Chen","year":"2012","journal-title":"Cancer Inform."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000519255","article-title":"Identifying High-Risk. Triple-Negative Breast Cancer Patients by Molecular Subtyping","volume":"16","author":"Hartung","year":"2021","journal-title":"Breast Care"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network (2012). Comprehensive molecular portraits of human breast tumours. Nature, 490, 61\u201370.","DOI":"10.1038\/nature11412"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1634\/theoncologist.2012-0397","article-title":"Molecular characterization of basal-like and non-basal-like triple-negative breast cancer","volume":"18","author":"Prat","year":"2013","journal-title":"Oncologist"},{"key":"ref_16","unstructured":"U.S. Food & Drug Administration, FDA (2022, October 20). Available online: www.fda.gov."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ravkin, H.D., Givton, O., Geffen, D.B., and Rubin, E. (2020). Direct comparison shows that mRNA-based diagnostics incorporate information which cannot be learned directly from genomic mutations. BMC Bioinform., 21.","DOI":"10.1186\/s12859-020-3512-z"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1913900","DOI":"10.1001\/jamanetworkopen.2019.13900","article-title":"Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer","volume":"2","author":"Karam","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.2006.09.1066","article-title":"Meta-analysis of BRCA1 and BRCA2 penetrance","volume":"25","author":"Chen","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3892\/or.2014.3685","article-title":"A novel PALB2 truncating mutation in an Italian family with male breast cancer","volume":"33","author":"Vietri","year":"2015","journal-title":"Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Piccolo, S.R., Andrulis, I.L., Cohen, A.L., Conner, T., Moos, P.J., Spira, A.E., Buys, S.S., Johnson, W.E., and Bild, A.H. (2015). Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. BMC Med. Genomics., 8.","DOI":"10.1186\/s12920-015-0145-6"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13058-021-01453-4","article-title":"Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use","volume":"23","author":"Schaafsma","year":"2021","journal-title":"Breast Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1185\/03007995.2015.1037730","article-title":"Prospective study of the impact of the Prosigna assay on adjuvant clinical decision-making in unselected patients with estrogen receptor positive, human epidermal growth factor receptor negative, node negative early-stage breast cancer","volume":"31","author":"Morales","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","article-title":"Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy","volume":"31","author":"Dowsett","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdt494","article-title":"Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: Using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone","volume":"25","author":"Gnant","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_26","unstructured":"Veracyte (2022, October 26). Prosigna Breast Cancer Assay. Available online: https:\/\/www.prosigna.com\/."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1200\/JCO.2017.74.6586","article-title":"PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer","volume":"36","author":"Jensen","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Soliman, H., Shah, V., Srkalovic, G., Mahtani, R., Levine, E., Mavromatis, B., Srinivasiah, J., Kassar, M., Gabordi, R., and Qamar, R. (2020). MammaPrint guides treatment decisions in breast Cancer: Results of the IMPACt trial. BMC Cancer, 20.","DOI":"10.1186\/s12885-020-6534-z"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"He","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update","volume":"40","author":"Andre","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s10549-016-3764-5","article-title":"Equivalence of MammaPrint array types in clinical trials and diagnostics","volume":"156","author":"Beumer","year":"2016","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10549-011-1683-z","article-title":"A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response","volume":"133","author":"Krijgsman","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40291-020-00482-7","article-title":"Oncotype DX Breast Recurrence Score\u00ae: A Review of its Use in Early-Stage Breast Cancer","volume":"24","author":"Syed","year":"2020","journal-title":"Mol. Diagn Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_36","unstructured":"Genomic Health (2022, November 07). What is the Oncotype DX\u00ae Test, and What Makes it Unique?. Available online: https:\/\/www.oncotypeiq.com\/en-CA\/breast-cancer\/healthcare-professionals\/oncotype-dx-breast-recurrence-score\/about-the-test#."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1200\/JOP.000075","article-title":"Coverage policy development for personalized medicine: Private payer perspectives on developing policy for the 21-gene assay","volume":"6","author":"Trosman","year":"2010","journal-title":"J. Oncol. Pract."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective Validation of a 21-Gene Expression Assay in Breast Cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer","volume":"380","author":"Sparano","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1001\/jamaoncol.2019.4794","article-title":"Clinical Outcomes in Early Breast Cancer with a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial","volume":"6","author":"Sparano","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1200\/JCO.2018.36.15_suppl.529","article-title":"Residual risk assessment with the Breast Cancer Index (BCI) for prediction of late distant recurrence (DR) in patients from the TransATAC study","volume":"36","author":"Sestak","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"R24","DOI":"10.1186\/bcr3402","article-title":"HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease","volume":"15","author":"Habel","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","article-title":"Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: A prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population","volume":"14","author":"Sgroi","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"M\u00fcller, B.M., Keil, E., Lehmann, A., Winzer, K.J., Richter-Ehrenstein, C., Prinzler, J., Bangemann, N., Reles, A., Stadie, S., and Schoenegg, W. (2013). The EndoPredict Gene-Expression Assay in Clinical Practice\u2014Performance and Impact on Clinical Decisions. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0068252"},{"key":"ref_46","unstructured":"Myriad Genetics (2022, November 27). EndoPredict: One Test\u2014Three Clinical Answers for Breast Cancer Patients. Available online: https:\/\/endopredict.eu\/."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1158\/1078-0432.CCR-11-0926","article-title":"A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors","volume":"17","author":"Filipits","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10549-019-05226-8","article-title":"Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone","volume":"176","author":"Sestak","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1158\/1078-0432.CCR-19-0376","article-title":"Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only","volume":"25","author":"Filipits","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"djw149","DOI":"10.1093\/jnci\/djw149","article-title":"Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy","volume":"108","author":"Buus","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.2021.39.15_suppl.537","article-title":"Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer","volume":"39","author":"Constantinidou","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_52","unstructured":"Veridex (2022, November 07). GeneSearch Breast Lymph Node (BLN) Test Kit, FDA Report\/PMA P060017. Available online: https:\/\/fda.report\/PMA\/P060017\/6\/P060017B.pdf."},{"key":"ref_53","unstructured":"Janssen Diagnostics (2022, November 02). GeneSearch\u2122 Breast Lymph Node (BLN) Assay Post Approval Study, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/record\/NCT00595296?view=record."},{"key":"ref_54","unstructured":"U.S. Food & Drug Administration (2022, November 02). Premarket Approval, PMA Number P060017, Genesearch Breast Lymph Node (Bln) Assay, Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfPMA\/pma.cfm?start_search=1&PMANumber=P060017."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejso.2008.06.033","article-title":"Intra-operative assessment of axillary sentinel lymph nodes (SLN) using an RT-PCR based assay for Mammaglobin (MG) and Cytokeratin 19 (CK19)","volume":"34","author":"Cutress","year":"2008","journal-title":"EJSO"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-008-0155-6","article-title":"Detection of breast cancer metastasis in sentinel lymph nodes using intra-operative real time GeneSearch BLN Assay in the operating room: Results of the Cardiff study","volume":"115","author":"Mansel","year":"2009","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_57","unstructured":"Agendia (2022, November 27). The Molecular Profile to Define and Defeat Her Unique Cancer. Available online: https:\/\/agendia.com\/mammaprint\/."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jmoldx.2019.04.007","article-title":"MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology","volume":"21","author":"Mittempergher","year":"2019","journal-title":"J. Mol. Diagn."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"609100","DOI":"10.3389\/fonc.2020.609100","article-title":"Genomic Assays in Node Positive Breast Cancer Patients: A Review","volume":"10","author":"Ibrahim","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_60","unstructured":"Biotheranostics, I. (2022, November 27). Breast Cancer Index. Available online: www.breastcancerindex.com."},{"key":"ref_61","unstructured":"Myriad Genetic Laboratories (2022, November 02). Myriad EndoPredict Technical Specifications. Available online: https:\/\/myriad-library.s3.amazonaws.com\/technical-specifications\/EndoPredict-Technical-Specifications.pdf."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"568","DOI":"10.2471\/BLT.18.207944","article-title":"Cost-effectiveness of risk-based breast cancer screening programme, China","volume":"96","author":"Sun","year":"2018","journal-title":"Bull. World Health Organ."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"7406","DOI":"10.1038\/s41598-021-86879-8","article-title":"Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis","volume":"11","author":"Holden","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"575461","DOI":"10.3389\/fonc.2020.575461","article-title":"Metastatic Breast Cancer and Pre-Diagnostic Blood Gene Expression Profiles-The Norwegian Women and Cancer (NOWAC) Post-Genome Cohort","volume":"10","author":"Olsen","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/AGG.S130004","article-title":"Local in Time Statistics for detecting weak gene expression signals in blood\u2014Illustrated for prediction of metastases in breast cancer in the NOWAC Post-genome Cohort","volume":"7","author":"Holden","year":"2017","journal-title":"Adv. Genom. Genet."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Chen, S., Liu, M., Liang, B., Ge, S., Peng, J., Huang, H., Xu, Y., Tang, X., and Deng, L. (2020). Identification of human peripheral blood monocyte gene markers for early screening of solid tumors. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230905"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1158\/1078-0432.CCR-07-1801","article-title":"Novel blood-based, five-gene biomarker set for the detection of colorectal cancer","volume":"14","author":"Han","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/diagnostics8010020","article-title":"The Role of Ultrasound in Screening Dense Breasts-A Review of the Literature and Practical Solutions for Implementation","volume":"8","author":"Thigpen","year":"2018","journal-title":"Diagnostics"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/bcr2092","article-title":"Breast cancer tumor growth estimated through mammography screening data","volume":"10","author":"Lindqvist","year":"2008","journal-title":"Breast Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3322\/caac.21583","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fgene.2019.00390","article-title":"Circular RNAs and RNA Splice Variants as Biomarkers for Prognosis and Therapeutic Response in the Liquid Biopsies of Lung Cancer Patients","volume":"10","author":"Gazzeri","year":"2019","journal-title":"Front. Genet."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2022.03.013","article-title":"The potential of liquid biopsy in the management of cancer patients","volume":"84","author":"Markou","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"ref_74","unstructured":"Ramanathan, L.V., Fleisher, M., and Duffy, M.J. (2022). Clinical Aspects and Laboratory Determination, Cancer Biomarkers, Elsevier."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.3390\/cancers13143600","article-title":"Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening","volume":"13","author":"Adashek","year":"2021","journal-title":"Cancers"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3390\/cancers12102767","article-title":"Non-Invasive Biomarkers for Early Detection of Breast Cancer","volume":"12","author":"Li","year":"2020","journal-title":"Cancers"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3390\/cancers12020298","article-title":"A Comprehensive Picture of Extracellular Vesicles and Their Contents. Molecular Transfer to Cancer Cells","volume":"12","author":"Jurj","year":"2020","journal-title":"Cancers"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.169.5.2756","article-title":"Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma","volume":"169","author":"Liyanage","year":"2002","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lab.2005.10.005","article-title":"The peripheral blood transcriptome dynamically reflects system wide biology: A potential diagnostic tool","volume":"147","author":"Liew","year":"2006","journal-title":"J. Lab. Clin. Med."},{"key":"ref_80","first-page":"6069","article-title":"Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma","volume":"63","author":"Twine","year":"2003","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Stoiber, D., and Assinger, A. (2020). Platelet-Leukocyte Interplay in Cancer Development and Progression. Cells, 9.","DOI":"10.3390\/cells9040855"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12943-021-01347-1","article-title":"Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?","volume":"20","author":"Ward","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"R634","DOI":"10.1186\/bcr1203","article-title":"Early detection of breast cancer based on gene-expression patterns in peripheral blood cells","volume":"7","author":"Sharma","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/bcr2472","article-title":"Gene expression profiling of peripheral blood cells for early detection of breast cancer","volume":"12","author":"Lindahl","year":"2010","journal-title":"Breast Cancer Res."},{"key":"ref_85","unstructured":"\u010cele\u0161nik, H.S. (2022, November 27). Triple-Negative Breast Cancer and other Breast Cancer. In: Encyclopedia. Available online: https:\/\/encyclopedia.pub\/entry\/21678."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ijc.29030","article-title":"Peripheral blood cells inform on the presence of breast cancer: A population-based case-control study","volume":"136","author":"Dumeaux","year":"2015","journal-title":"Int. J. Cancer."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s12282-018-0920-2","article-title":"Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients","volume":"26","author":"Suzuki","year":"2019","journal-title":"Breast Cancer"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"781618","DOI":"10.1155\/2013\/781618","article-title":"Multiple biomarker panels for early detection of breast cancer in peripheral blood","volume":"2013","author":"Zhang","year":"2013","journal-title":"Biomed. Res. Int."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Hou, H., Lyu, Y., Jiang, J., Wang, M., Zhang, R., Liew, C.C., Wang, B., and Cheng, C. (2020). Peripheral blood transcriptome identifies high-risk benign and malignant breast lesions. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0233713"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccell.2020.05.021","article-title":"Pan-Cancer Early Detection: Hype or Hope?","volume":"38","author":"Srivastava","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"746879","DOI":"10.3389\/fgene.2021.746879","article-title":"Complex Age- and Cancer-Related Changes in Human Blood Transcriptome-Implications for Pan-Cancer Diagnostics","volume":"12","author":"Qi","year":"2021","journal-title":"Front. Genet."},{"key":"ref_92","first-page":"e19189","article-title":"Tumor-Educated Platelets: A Review of Current and Potential Applications in Solid Tumors","volume":"13","author":"Varkey","year":"2021","journal-title":"Cureus"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.ccell.2015.09.018","article-title":"RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics","volume":"28","author":"Best","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.4161\/cbt.10.12.13437","article-title":"Using peripheral blood mRNA signature to distinguish between breast cancer and benign breast disease in non-conclusive mammography patients","volume":"10","author":"Yang","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/ijc.27933","article-title":"Altered local and systemic immune profiles underlie lymph node metastasis in breast cancer patients","volume":"132","author":"Zuckerman","year":"2013","journal-title":"Int. J. Cancer."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Lund, E., Holden, L., B\u00f8velstad, H., Plancade, S., Mode, N., G\u00fcnther, C.C., Nuel, G., Thalabard, J.C., and Holden, M. (2016). A new statistical method for curve group analysis of longitudinal gene expression data illustrated for breast cancer in the NOWAC postgenome cohort as a proof of principle. BMC Med. Res. Methodol., 16.","DOI":"10.1186\/s12874-016-0129-z"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ije\/dym137","article-title":"Cohort profile: The Norwegian Women and Cancer Study--NOWAC--Kvinner og kreft","volume":"37","author":"Lund","year":"2008","journal-title":"Int. J. Epidemiol."},{"key":"ref_98","unstructured":"\u010cele\u0161nik, H.S. (2022, November 08). Breast Cancer Biomarkers from Peripheral Blood Cells. In: Encyclopedia. Available online: https:\/\/encyclopedia.pub\/entry\/21624."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3239167","DOI":"10.1155\/2016\/3239167","article-title":"Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients","volume":"2016","author":"Balacescu","year":"2016","journal-title":"Mediators Inflamm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2018.02028","article-title":"Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells from Patients with Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer","volume":"9","author":"Foulds","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3389\/fonc.2019.00985","article-title":"Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients with an Unsupervised Analysis","volume":"9","author":"Ming","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Dumeaux, V., Fjukstad, B., Fjosne, H.E., Frantzen, J.O., Holmen, M.M., Rodegerdts, E., Schlichting, E., B\u00f8rresen-Dale, A.L., Bongo, L.A., and Lund, E. (2017). Interactions between the tumor and the blood systemic response of breast cancer patients. PLoS Comput. Biol., 13.","DOI":"10.1371\/journal.pcbi.1005680"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1023\/B:JOMG.0000048770.90334.3b","article-title":"The genetic epidemiology of breast cancer genes","volume":"9","author":"Thompson","year":"2004","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejca.2017.12.025","article-title":"The future of blood-based biomarkers for the early detection of breast cancer","volume":"92","author":"Loke","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/j.clbc.2021.09.006","article-title":"Circulating Biomarkers in Breast Cancer","volume":"22","author":"Seale","year":"2022","journal-title":"Clin. Breast Cancer"},{"key":"ref_106","unstructured":"Ambry Genetics (2022, November 08). +RNAinsight, Expanded RNA Analysis for Better Variant Classification. Available online: https:\/\/www.ambrygen.com\/file\/material\/view\/1663\/RNA_Flyer_FNL%20091521.pdf."},{"key":"ref_107","unstructured":"Syantra (2022, November 08). Syantra DX|Breast Cancer FAQs. Available online: https:\/\/ss-usa.s3.amazonaws.com\/c\/308494115\/media\/1619629a43fbddb7823212636145172\/4115~collateral_FAQs_c.pdf."},{"key":"ref_108","unstructured":"(2022, November 08). Syantra. Available online: https:\/\/www.syantra.com\/."},{"key":"ref_109","unstructured":"StageZero (2022, November 08). Aristotle\u00ae. Available online: https:\/\/www.stagezerolifesciences.com\/aristotle-test.html."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S1359-6349(10)71449-X","article-title":"Use of the blood based, 96-assay set for breast cancer detection. Poster","volume":"8","author":"Tobin","year":"2010","journal-title":"EJC Suppl."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"11012","DOI":"10.1200\/jco.2009.27.15_suppl.11012","article-title":"Performance of a blood-based gene-expression test, BCtect, for early breast cancer detection","volume":"27","author":"Tobin","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"vii334","DOI":"10.1093\/annonc\/mdq365","article-title":"Genetic counselling for hereditary predisposition to ovarian and breast cancer","volume":"21","author":"Mackay","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Karam, R., Krempely, K., Richardson, M., McGoldrick, K., Conner, B.R., Landrith, T., Allen, K., Yussuf, A., Rana, H., and Culver, S. (2019, January 2\u20136). RNA Genetic Testing in Hereditary Cancer Improves Variant Classification and Patient Management. In Proceedings of the Annual Clinical Genetics Meeting (ACMG), Seattle, DC, USA.","DOI":"10.1001\/jamanetworkopen.2019.13900"},{"key":"ref_114","unstructured":"Ambry Genetics (2023, January 24). First Prospective Study Shows +RNAinsight\u2122 Identifies More Patients with Increased Risk for Hereditary Cancer Than DNA-Only Testing. Available online: https:\/\/www.ambrygen.com\/company\/press-release\/128\/first-prospective-study-shows-rnainsight-identifies-more-patients-with-increased-risk-for-hereditary-cancer-than-dna-only-testing."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"P2\u201301\u201302","DOI":"10.1158\/1538-7445.SABCS21-P2-01-02","article-title":"Abstract P2-01-02: A whole blood assay to identify breast cancer: Interim analysis of the international identify breast cancer (IDBC) study evidence supporting the Syantra DX breast cancer test","volume":"82","author":"Bundred","year":"2022","journal-title":"Cancer Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e15037","DOI":"10.1200\/JCO.2020.38.15_suppl.e15037","article-title":"Aristotle: A single blood test for pan-cancer screening","volume":"38","author":"Dempsey","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_117","unstructured":"DiaGenic ASA and Applied Biosystems (2022, November 27). Diagenic Announces Launch of First Breast Cancer Gene-Expression Blood Test. Available online: https:\/\/www.medindia.net\/health-press-release\/Diagenic-Announces-Launch-of-First-Breast-Cancer-Gene-Expression-Blood-Test-37529-1.htm."},{"key":"ref_118","unstructured":"Cision, C.E. (2022, November 27). Marking of the DiaGenic\u2019s Blood Test for Early Breast Cancer Diagnosis. Available online: https:\/\/news.cision.com\/nel-asa\/r\/ce-marking-of-the-diagenic-s-blood-test-for-early-breast-cancer-diagnosis,c434534."},{"key":"ref_119","unstructured":"Elvidge, S. (2022, November 27). Gene Expression Diagnostics: A New Approach. In: Life Science Leader. Available online: https:\/\/www.lifescienceleader.com\/doc\/gene-expression-diagnostics-a-new-approach-0001."},{"key":"ref_120","unstructured":"Park, A. (2022, November 08). Freenome, Siemens Join Forces to Develop Blood Test for Breast Cancer. Available online: https:\/\/www.fiercebiotech.com\/medtech\/freenome-siemens-join-forces-to-develop-blood-test-for-breast-cancer."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1089\/genedge.4.1.06","article-title":"Blood Stake: Roche Raises Freenome Investment to $360M","volume":"4","author":"Philippidis","year":"2022","journal-title":"GEN Edge"},{"key":"ref_122","unstructured":"Stephens, K. (2022, November 27). Freenome, Siemens Healthineers Collaborate for Breast Cancer Research. Available online: https:\/\/www.proquest.com\/."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrg.2016.10","article-title":"Translating RNA sequencing into clinical diagnostics: Opportunities and challenges","volume":"17","author":"Byron","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/clinchem\/48.8.1178","article-title":"Real-time PCR technology for cancer diagnostics","volume":"48","author":"Bernard","year":"2002","journal-title":"Clin. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Gr\u00e4tz, C., Bui, M.L.U., Thaqi, G., Kirchner, B., Loewe, R.P., and Pfaffl, M.W. (2022). Obtaining Reliable RT-qPCR Results in Molecular Diagnostics-MIQE Goals and Pitfalls for Transcriptional Biomarker Discovery. Life, 12.","DOI":"10.3390\/life12030386"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.7150\/jca.24744","article-title":"Gene Expression Detection Assay for Cancer Clinical Use","volume":"9","author":"Narrandes","year":"2018","journal-title":"J. Cancer"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Kamps, R., Brand\u00e3o, R.D., Bosch, B.J., Paulussen, A.D., Xanthoulea, S., Blok, M.J., and Romano, A. (2017). Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18020308"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1002\/ctm2.782","article-title":"Forward single-cell sequencing into clinical application: Understanding of cancer microenvironment at single-cell solution","volume":"12","author":"Liu","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e671","DOI":"10.1002\/ctm2.671","article-title":"Can single cell RNA sequencing reshape the clinical biochemistry of hematology: New clusters of circulating blood cells","volume":"11","author":"Fang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kamps-Hughes, N., Carlton, V.E.H., Fresard, L., Osazuwa, S., Starks, E., Vincent, J.J., Albritton, S., Nussbaum, R.L., and Nykamp, K. (2022). A Systematic Method for Detecting Abnormal mRNA Splicing and Assessing Its Clinical Impact in Individuals Undergoing Genetic Testing for Hereditary Cancer Syndromes. J. Mol. Diagn.","DOI":"10.1101\/2022.07.12.499782"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2021.06.003","article-title":"BRCA1 and BRCA2 whole cDNA analysis in unsolved hereditary breast\/ovarian cancer patients","volume":"258\u2013259","author":"Montalban","year":"2021","journal-title":"Cancer Genet."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.cll.2020.02.001","article-title":"Enhancing Diagnosis Through RNA Sequencing","volume":"40","author":"Murdock","year":"2020","journal-title":"Clin. Lab. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40142-021-00199-x","article-title":"The Role of RNA-Sequencing as a New Genetic Diagnosis Tool","volume":"9","author":"Curry","year":"2021","journal-title":"Curr. Genet. Med. Rep."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/s41591-019-0457-8","article-title":"Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts","volume":"25","author":"Smail","year":"2019","journal-title":"Nat. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"eaal5209","DOI":"10.1126\/scitranslmed.aal5209","article-title":"Improving genetic diagnosis in Mendelian disease with transcriptome sequencing","volume":"9","author":"Cummings","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41698-020-0109-y","article-title":"Splicing profile by capture RNA-seq identifies pathogenic germline variants in tumor suppressor genes","volume":"4","author":"Landrith","year":"2020","journal-title":"NPJ Precis Oncol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/gim.2018.38","article-title":"False-positive results released by direct-to-consumer genetic tests highlight the importance of clinical confirmation testing for appropriate patient care","volume":"20","author":"Guiltinan","year":"2018","journal-title":"Genet. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/jco.2012.30.30_suppl.69","article-title":"A blood-based gene expression signature of early-stage non-small cell lung cancer","volume":"30","author":"Rotunno","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/0008-5472.CAN-19-3684","article-title":"Platelet RNA as Pan-Tumor Biomarker for Cancer Detection","volume":"80","author":"Wurdinger","year":"2020","journal-title":"Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1210\/jc.2018-01804","article-title":"Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease","volume":"104","author":"Malczewska","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MCG.0000000000000112","article-title":"Blood gene signature for early hepatocellular carcinoma detection in patients with chronic hepatitis B","volume":"49","author":"Omar","year":"2015","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"e71035","DOI":"10.7554\/eLife.71035","article-title":"Serum RNAs can predict lung cancer up to 10 years prior to diagnosis","volume":"11","author":"Umu","year":"2022","journal-title":"Elife"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/1878-0261.12620","article-title":"A 10-year prediagnostic follow-up study shows that serum RNA signals are highly dynamic in lung carcinogenesis","volume":"14","author":"Umu","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"574977","DOI":"10.3389\/fonc.2020.574977","article-title":"Serum RNA Profiling in the 10-Years Period Prior to Diagnosis of Testicular Germ Cell Tumor","volume":"10","author":"Burton","year":"2020","journal-title":"Front Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Nielsen, T., Wallden, B., Schaper, C., Ferree, S., Liu, S., Gao, D., Barry, G., Dowidar, N., Maysuria, M., and Storhoff, J. (2014). Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-177"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.tranon.2019.08.008","article-title":"Decentralization of Next-Generation RNA Sequencing-Based MammaPrint\u00ae and BluePrint\u00ae Kit at University Hospitals Leuven and Curie Institute Paris","volume":"12","author":"Slembrouck","year":"2019","journal-title":"Transl. Oncol."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Kronenwett, R., Bohmann, K., Prinzler, J., Sinn, B.V., Haufe, F., Roth, C., Averdick, M., Ropers, T., Windbergs, C., and Brase, J.C. (2012). Decentral gene expression analysis: Analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test. BMC Cancer, 12.","DOI":"10.1186\/1471-2407-12-456"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s12282-012-0437-z","article-title":"GeneSearch\u2122 BLN Assay could replace frozen section and touch imprint cytology for intra-operative assessment of breast sentinel lymph nodes","volume":"21","author":"Wang","year":"2014","journal-title":"Breast Cancer"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1038\/ejhg.2016.63","article-title":"Guidelines for diagnostic next-generation sequencing","volume":"24","author":"Matthijs","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10147-020-01831-6","article-title":"Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1)","volume":"26","author":"Naito","year":"2021","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.molonc.2007.10.004","article-title":"TRANSBIG Consortium. The MINDACT trial: The first prospective clinical validation of a genomic tool","volume":"1","author":"Cardoso","year":"2007","journal-title":"Mol. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s10549-017-4509-9","article-title":"MINDACT investigators. Immunohistochemical versus molecular (BluePrint and MammaPrint) subtyping of breast carcinoma. Outcome results from the EORTC 10041\/BIG 3-04 MINDACT trial","volume":"167","author":"Viale","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/jnci\/djaa148","article-title":"Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial","volume":"113","author":"Albain","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jmoldx.2017.11.003","article-title":"Standards and Guidelines for Validating Next-Generation Sequencing Bioinformatics Pipelines: A Joint Recommendation of the Association for Molecular Pathology and the College of American Pathologists","volume":"20","author":"Roy","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s13206-021-00020-5","article-title":"Understanding Confounding Effects of Blood Handling Strategies on RNA Quality and Transcriptomic Alteration Using RNA Sequencing","volume":"15","author":"Koh","year":"2021","journal-title":"BioChip J."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Park, S., Ahn, S., Kim, J.Y., Kim, J., Han, H.J., Hwang, D., Park, J., Park, H.S., Park, S., and Kim, G.M. (2022). Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23169140"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"100006","DOI":"10.1016\/j.esmoop.2020.100006","article-title":"A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort","volume":"6","author":"Dubsky","year":"2021","journal-title":"ESMO Open"},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Wylezinski, L.S., Shaginurova, G.I., and Spurlock Iii, C.F. (2020). Longitudinal assessment and stability of long non-coding RNA gene expression profiles measured in human peripheral whole blood collected into PAXgene blood RNA tubes. BMC Res. Notes, 13.","DOI":"10.1186\/s13104-020-05360-3"},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Donohue, D.E., Gautam, A., Miller, S.A., Srinivasan, S., Abu-Amara, D., Campbell, R., Marmar, C.R., Hammamieh, R., and Jett, M. (2019). Gene expression profiling of whole blood: A comparative assessment of RNA-stabilizing collection methods. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0223065"},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Asare, A.L., Kolchinsky, S.A., Gao, Z., Wang, R., Raddassi, K., Bourcier, K., and Seyfert-Margolis, V. (2008). Differential gene expression profiles are dependent upon method of peripheral blood collection and RNA isolation. BMC Genom., 9.","DOI":"10.1186\/1471-2164-9-474"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.2147\/OTT.S158868","article-title":"Impact of RNA integrity and blood sample storage conditions on the gene expression analysis","volume":"11","author":"Shen","year":"2018","journal-title":"Onco. Targets Ther."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1006\/abio.1996.0432","article-title":"Real-time DNA sequencing using detection of pyrophosphate release","volume":"242","author":"Ronaghi","year":"1996","journal-title":"Anal. Biochem."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/bib\/bbz027","article-title":"Platform-independent approach for cancer detection from gene expression profiles of peripheral blood cells","volume":"21","author":"Yang","year":"2020","journal-title":"Brief. Bioinform."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/1087\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:28:11Z","timestamp":1760120891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/1087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":163,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15041087"],"URL":"https:\/\/doi.org\/10.3390\/cancers15041087","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}